In response to Toll-like receptor ligands, dendritic cells (DCs) dramatically enhance their antigen presentation capacity by stabilizing at the cell-surface MHC II molecules. We demonstrate here that, in human monocyte-derived DCs, the RING-CH ubiquitin E3 ligase, membrane-associated RING-CH I (MARCH I), promotes the ubiquitination of the HLA-DR ␤-chain. Thus, in nonactivated DCs, MARCH I induces the surface internalization of mature HLA-DR complexes, therefore reducing their stability and levels. We further demonstrate that the maturation-dependent down-regulation of MARCH I is a key event in MHC class II up-regulation at the surface of LPS-activated DCs. MARCH I is, therefore, a major regulator of HLA-DR traffic, and its loss contributes to the acquisition of the potent immunostimulatory properties of mature human DCs.
A ctivation of dendritic cells (DCs) by invading pathogens involves a process of maturation that converts an immature DC (iDC) to a mature DC (mDC) and a subsequent Toll-like receptor (TLR)-mediated immune response. This process is accompanied by a marked cellular reorganization (1, 2) . Redistribution of MHC class II molecules (MHC class II) from late endosomal compartments to the plasma membrane (3) represents one of the major functional events observed during the acquisition of the immunostimulatory function by mDCs. Recently in mouse DCs, ubiquitination of lysine-225 in the cytoplasmic tail of MHC II ␤-chain has been shown to be determinant for the targeting and accumulation of the mature form of MHC II in the lysosomes of iDCs (4, 5) . Interestingly, ubiquitination of MHC II in murine DCs ceases on maturation, thus contributing to the increased level of MHC II at the cell surface (4, 5) . Membrane-associated RING-CH (MARCH) proteins represent a family of E3 ubiquitin ligases, which all contain a variant catalytical RING-finger domain (RING-CH domain, C4HC3) located at the N terminus (6) (7) (8) (9) (10) . It has been recently reported that transgenic overexpression of MARCH VIII/c-MIR in mouse splenic antigen-presenting cells (APCs) leads to internalization of surface CD86/B7-2 and MHC II, and subsequent lysosomal degradation (10) . Furthermore, deletion of MARCH I, another E3 ubiquitin ligase, promoted an increase of surface MHC II levels in mouse B cells, although a direct implication of this ligase in the process of MHC II internalization was excluded (11) . We identify here human MARCH I as a potent regulator of HLA-DR surface expression and explore its role during human monocyte-derived DC (MoDC) activation. We further show that MARCH I expression is lost at late stages of DC maturation and thereby participates in the stabilization of peptideloaded HLA-DR at the cell surface. Our observations suggest that MARCH I is essential to coordinate MHC II-restricted antigen presentation during human DC activation by TLR ligands.
Results

MHC Class II Ubiquitination Is Regulated in MoDCs. The subcellular localization of MHC class II (HLA-DR) in CD14
ϩ MoDCs changes dramatically when cells are exposed to LPS (12, 13) . As determined by confocal microscopy, iDCs accumulate HLA-DR molecules in LAMP1 ϩ late endosomes and lysosomes. On activation by LPS, rapid relocalization of MHC II to the cell surface is observed (4-8 h) [supporting information (SI) Fig. 7A ]. Recently, this process has been shown to be associated with a loss of ubiquitination on the class II ␤-chain in mouse bone marrow-derived DCs (bmDCs) (4, 5) . We investigated whether the control of HLA-DR traffic was also mediated by ubiquitination in human MoDCs. HLA-DR molecules were immunoprecipitated at different times of maturation by using peptide-loaded HLA-DR-specific L243 antibodies ( Fig. 1A ) (see SI Materials and Methods). On immunoblotting with the P4D1 antiubiquitin antibody, HLA-DR ubiquitination was detected in immature MoDCs. In addition to the characteristic polyubiquitinated proteins ladder, monoubiquitinated MHC II (Ϸ37 kDa) appeared to be the prevalent form found in human iDCs. Interestingly, HLA-DR ubiquitination rapidly decreased with maturation and was fully abrogated after 16 h. Fig. 1B shows immunoprecipitated HLA-DR ␣␤ dimers (left lanes), which were boiled and further immunoprecipitated by using the anti HLA-DR ␤-chain-specific antibody XD5 (right lanes). Immunoblot detection with P4D1 of the two different immunoisolates confirmed that reversible MHC II ubiquitination occurs specifically and probably uniquely on HLA-DR ␤-chain (37-kDa band). The ratio between ubiquitinated and unmodified HLA-DR forms indicated that only a relatively small proportion of all of the ␤-chain molecules were modified at steady state. Immunoprecipitation of total lysates with an antiinvariant chain antibody failed to reveal any ubiquitination of invariant chain-MHC class II complexes, indicating that in humans only mature peptide-loaded HLA-DR complexes are regulated by ␤-chain ubiquitination (SI Fig. 7B ).
Overexpression of MARCH I Down-Regulates Surface MHC Class II.
MARCH proteins are E3 ubiquitin ligases that have been reported to down-regulate several surface molecules including transferrin receptor (TfR), MHC class I and II, and CD86 (7, 10) . We evaluated the capacity of different human MARCH ligases to control HLA-DR surface expression through transfection of class II transactivator (CIITA)-expressing HeLa cells (14) . Different mRNAs, coding for MARCH I through MARCH IX fused with an
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eGFP moiety were transfected in HeLa-CIITA cells, before FACS analysis ( Fig. 2A Upper) . Surface HLA-DR levels were affected by the overexpression of MARCH I-eGFP and also, as expected, by MARCH VIII-eGFP (10). We thereby tested whether a single lysine residue in the cytoplasmic tail of the MHC-II ␤-chain was required by MARCH I to induce HLA-DR surface downregulation. We transiently expressed in HEK293T cells the HLA-DR ␣-chain together with two different HLA-DR ␤ cDNA constructs, containing either a wild-type (␤) or a mutated cytoplasmic tail, with an alanine replacement at position 225 (␤K225A). On MARCH I expression, down-regulation was heavily impaired for ␤K225A-bearing MHC II dimers ( Fig. 2 A Lower) , thus identifying lysine-225 as a target residue for MARCH I-driven ubiquitination on HLA-DR.
To confirm the relevance of MARCH I in mediating MHC II down-regulation in human DCs, surface expression of peptideloaded MHC II was analyzed by FACS after MARCH I-eGFP mRNAs transfection. Despite a modest MARCH I expression (SI Fig. 8 ), surface levels of mature MHC II were strongly downregulated in transfected MoDCs (Fig. 2B) . Surface CD86 upregulation, normally occurring on DC maturation, was also prevented. Yet, MARCH I targets a restricted number of surface proteins because the lipid-antigen presenting molecule CD1a was not affected by its overexpression. Consistently with the downregulation of surface MHC II, MARCH I overexpression in MoDCs also induced an important increase in DR ␤-chain ubiquitination (Fig. 2C) . Although the transfection procedure was found to induce DC maturation and the subsequent reduction of MHC II ubiquitination (control eGFP), MARCH I expression restored ubiquitination levels, which were quantitatively and qualitatively very similar to the ladder observed in nontransfected iDCs.
Immunofluorescence confocal microscopy of MARCH Ioverexpressing MoDCs revealed an enhanced accumulation of mature HLA-DR in late endosomal/lysosomal compartments (Fig.  2D ). L243 mAb, being specific for Ii chain-free ␣␤ HLA-DR dimers, labels predominantly the plasma membrane of DCs at all maturation stages. On MARCH I overexpression, we could observe a loss of L243-positive MHC II plasma membrane staining and an increased colocalization with HLA-DM compared with eGFP-and MARCH II-transfected cells. MARCH I is therefore also likely to promote late endosomal sorting of mature MHC II dimers.
We followed the fate of surface MHC II molecules on cold binding of L243 antibody at the cell surface, followed by incubation at 37°C for different times, and subsequent cell lysis and immunoprecipitation (Fig. 3A) . Quantification of precipitated material by immunoblot revealed that MARCH I rapidly promotes a 40% reduction of L243-bound MHC II in transfected DCs. This loss likely represents a rapid degradation of internalized surface MHC II, consistent with a prolonged exposure to the acidic environment of late endocytic compartments. However, the dissociation of the immune complex could lead to an overestimation of the efficiency of this process.
Indeed, confocal microscopy analysis indicated that L243-bound DR molecules reached endosomal compartments more efficiently in MARCH I-transfected than control DCs (Fig. 3B ). Heterologous expression of MARCH I therefore induces a dominant ''immaturelike'' DC phenotype, likely via increased MHC II ubiquitination and subsequent targeting to the endocytic pathway.
MARCH I Expression Is Regulated During DC Maturation. Based on our observations on MARCH I activity and its role in MHC II traffic, we reasoned that this ligase may be submitted to transcriptional regulation specifically on LPS-driven maturation. mRNA extraction and RT-PCR of all MARCH transcripts were performed in different human cell lines, and CD14 ϩ monocytes and LPS-treated MoDCs (Fig. 4A) . MARCH mRNAs were expressed in all cell types tested, with the exception of MARCH I and IV. Strikingly, MARCH I expression, although restricted to professional APCs, was not detected in mature DCs (Fig. 4A, lane 2) . Real-time quantitative PCR confirmed that MARCH I transcription was rapidly (4 h) and strongly down-regulated (20-fold after 24 h) on LPS-induced maturation (Fig. 4B) . MARCH II and VIII mRNA levels, however, showed no significant variations during maturation. Similar results were obtained testing cells from several different blood donors and were in full agreement with data generated by an independent Affymetrix pangenome chip analysis of maturing MoDCs mRNA (SI Fig. 9 ).
Because MARCH protein expression is poorly detectable in MoDCs, MARCH I was enriched by immunoprecipitation before immunoblot detection with antibodies validated in cells transfected with MARCH-eGFP chimeras (SI Fig. 10 ). In agreement with its decreased transcription, the level of MARCH I protein was found to be reduced after 4 h of maturation and nondetectable after 24 h (Fig. 4C) . MARCH I down-regulation is therefore a previously undescribed feature of LPS-driven MoDC maturation and is tightly correlated with the loss of MHC II ubiquitination and its increased surface stabilization.
MARCH I Regulates Surface MHC Class II Levels During DC Activation.
Our observations, mainly based on overexpression experiments, implicate MARCH I in the ubiquitination and the control of surface MHC II molecule internalization in iDCs. To study further the effects of endogenous MARCH I activity on MHC II and CD86 dynamic in DCs, we artificially down-regulated MARCH I expression in iDCs by using nucleoporation of specific siRNA. The efficiency and selectivity of the RNAi procedure in transfected cells was established by following MARCH I-eGFP chimera expression by FACS and immunoblot (SI Fig. 10 ).
Artificial MARCH I mRNA depletion in iDCs (equivalent to the down-modulation levels reached on 4 h of LPS treatment) resulted in a clear increase of HLA-DR and CD86 surface levels, whereas CD1a expression remained constant (Fig. 5 A and B) . We tested next the effect of MARCH I depletion on HLA-DR ubiquitination in iDCs. MHC II complexes were immunoprecipitated with L243 from cells submitted to MARCH I RNAi, and HLA-DR ubiquitination was monitored by immunoblot (Fig. 5C ). MARCH I depletion resulted in an important reduction (50%) of ubiquitinated HLA-DR, consistent with the concomitant increase in MHC II and CD86 surface levels observed by FACS (Fig. 5A) . MARCH I transcriptional and translational down-regulation during MoDCs activation appears therefore to be a major event leading to the inhibition of MHC II ubiquitination and surface stabilization in mature human DCs.
MARCH I Controls MHC Class II Internalization. To determine at which level MHC class II transport might be affected by MARCH I depletion, we established the subcellular localization of HLA-DR molecules by confocal microscopy in MARCH I RNAi-treated iDCs (Fig. 6A) . In addition to the expected late endosomal localization (HLA-DM ϩ ) observed normally in iDCs, MARCH I depletion induced the accumulation of HLA-DR molecules in EEA1 ϩ sorting endosomes and at the plasma membrane. This result was confirmed by quantification of colocalization of MHC II either with HLA-DM-or with EEA1-positive compartments by using the Pearson coefficient method (Fig. 6B) . The early endosomal accumulation of HLA-DR is in agreement with MARCH I subcellular distribution (SI Fig. 11 ), which is mostly restricted to early endosomes and to the plasma membrane of transfected cells. In addition, endocytosis inhibitors such as bafilomycin and dynasore [recently characterized as a cell-permeable inhibitor of dynamin (15)] counteract MARCH I activity by preventing MHC II surface downregulation in transfected HeLa-CIITA cells (SI Fig. 11 ), thus confirming that this ligase plays a major role in surface MHC II internalization and/or early endosomal sorting. We finally evaluated the impact of MARCH I depletion on the internalization rate of mature HLA-DR, monitoring the percentage of L243 antibody remaining at the surface of maturing MoDCs over time (Fig. 6C Upper) . As anticipated, MHC II-antibody complex internalization was significantly reduced in cells treated with LPS for 24 h, whereas nonactivated DCs displayed an efficient endocytic activity. When MARCH I was artificially down-regulated in iDCs (Fig. 6C Lower) , the reduction of MHC II internalization was strikingly similar to the situation observed in mature DCs. Indeed, the uptake over 1 h of the L243 antibody was decreased by 50% (shown here for two representative blood donors), thus confirming the importance of MARCH I in mediating surface internalization of mature MHC II molecules. The same experiment performed with an anti-TfR antibody failed to reveal any difference in its endocytosis rate in absence of MARCH I, thus confirming the specificity of this E3 ligase for MHC II (SI Fig. 12 ).
Discussion
We analyzed here the molecular mechanism leading to the maturation-dependent HLA-DR and CD86 surface up-regulation required by human DCs to acquire their immunostimulating properties. We have identified the down-regulation of the E3 ubiquitin ligase MARCH I as a major biochemical event leading to MHC II surface stabilization during DC activation. We showed that HLA-DR ␤-chain ubiquitination is promoted by MARCH I in human immature MoDCs. MARCH I favors the direct internalization of peptide-loaded MHC II from the cell surface, likely weakening the antigen presentation capacity of immature DCs. The maturation-dependent loss of MARCH I prevents the ubiquitination-mediated internalization of HLA-DR resulting in full DC activation. Consistent with this hypothesis, the depletion of MARCH I in iDCs reduces dramatically MHC II ubiquitination levels and enhances its plasma membrane stabilization, thus recapitulating DC functional maturation.
We demonstrated the existence of human ubiquitinated HLA-DR molecules, indicating that mono-and polyubiquitination are evolutionally conserved endosomal sorting signals required for the regulation of MHC II traffic. Although down-regulation of cell-surface HLA-DR is almost complete in MARCH I-transfected DCs and large amounts of MHC-II molecules are detected in lysosomes, only a very small fraction of total DR was found to be ubiquitinated. This suggests that MHC II molecules may be efficiently deubiquitinated, most probably in late endosomes as shown for other cargo molecules (16) .
Recent work on the effect of MARCH I deletion in mouse B cells excluded a direct implication of MARCH I in the process of MHC II internalization (11) . Our divergent finding on MARCH I role in the earliest steps of MHC II endocytosis may be due to the different experimental settings, in particular the utilization of RNA interference to deplete MARCH I in human DCs instead of a full genetic inactivation as in KO mice, which could lead to compensatory mechanisms. In addition, we could show that pharmacological inhibition of dynamin-mediated surface internalization with dynasore (SI Fig. 11 ) impaired MARCH I-induced MHC II downregulation, further supporting an implication of this ligase in HLA-DR surface uptake. Moreover, consistent with the mouse KO data, we find that human MARCH I is also involved in MHC II early endosomal sorting, as suggested by HLA-DR accumulation in EEA ϩ compartments in MARCH I-depleted cells. Several ubiquitin ligases are likely to be involved in MHC II internalization and endosomal targeting. In particular, the role of MARCH VIII, which is ubiquitously expressed (7), remains to be investigated. Its ubiquitous tissue expression pattern, taken together with the fact that MARCH VIII does not undergo any major maturation-dependent transcriptional regulation in DCs, suggests that MARCH VIII may have other functions in this cell type. Like most E3 ubiquitin-ligases, MARCH proteins have multiple substrates and both MARCH I and VIII have been shown to downregulate also Fas (CD95) and TfR (7). The main physiological The existence of different MARCH ubiquitin ligases in DCs, each of them specific for distinct targets and endocytic steps, might ensure the correct sorting of neosynthesized and peptide-loaded MHC II complexes, and immunomodulatory molecules (e.g., CD86). The tolerogenic properties of DCs harboring a relatively weak stimulatory activity (17, 18) may be linked to the rapid internalization of surface MHC II complexes and CD86. Indeed, previous studies report that tolerogenic cytokines, such as IL-10, can interfere with DC maturation by impairing surface accumulation of MHC II and costimulatory molecules (19) . The fate of MARCH ligases on DC exposure to tolerogenic cytokines will have therefore to be carefully investigated.
Materials and Methods
Cell Culture. To promote differentiation into iDC, purified CD14 ϩ cells (0.5 ϫ 10 6 cells per ml) were plated in six-well plates (2 ϫ 10 6 cells per well) and cultured in RPMI medium 1640 supplemented with 10% FCS, nonessential amino acids, penicillin/streptomycin at 100 ng/ml (Ͼ1,000 units/ml), recombinant human GM-CSF, and 20 ng/ml (Ͼ100 units/ml) IL-4 for 5 days (both from PeproTech).
Immunocytochemistry. DCs were harvested and let adhere on 1% Alcian bluetreated coverslips for 10 min at 37°C, fixed with 3% paraformaldehyde in PBS for 10 min at room temperature, permeabilized with 0.1% saponin in PBS/5% FCS/100 mM glycine for 10 min at room temperature, and stained 1 h with indicated primary antibody. All Alexa secondary antibodies were from Molecular Probes. Immunofluorescence and confocal microscopy (using microscope model LSM 510; Carl Zeiss MicroImaging) were performed as described in ref. 20 .
Cell Transfection. mRNA HeLa-CIITA transfections were performed by using Lipofectamine2000 Reagents (Invitrogen) following the manufacturer's instructions. For mRNA transfections, immature DCs were harvested at day 6 of culture and resuspended in the specified Amaxa electroporation buffer (Human Dendritic Cell Nucleofector kit; Amaxa) to a final concentration of 3 ϫ 10 7 cells per ml. A total of 15 g of in vitro transcribed mRNA was mixed with 0.1 ml of cell suspension, transferred to a 2.0-mm electroporation cuvette, and nucleofected with an Amaxa Nucleofector apparatus as indicated by the manufacturer.
mRNA Quantification by Real-Time RT-PCR. PCR was carried out in complete SYBR Green PCR buffer (PE Biosystems) by using 200 nM of each specific primer. A total of 20 l of PCR mix was added to 5 l of cDNA template, and the amplification was tracked via SYBR Green incorporation by using a Stratagene sequence detection system. cDNA concentration in each sample were normalized by using GAPDH. A nontemplate control was also routinely performed. 
Antibodies
